Naoko Matsunaga

Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing

Laura Riva, Shuofeng Yuan, Xin Yin et al. · Nature · 2020 · 837 citations · Full text

Large-scale Compound Repurposing, Medicine, Antiviral Drug Development +5

TAK-242 (Resatorvid), a Small-Molecule Inhibitor of Toll-Like Receptor (TLR) 4 Signaling, Binds Selectively to TLR4 and Interferes with Interactions between TLR4 and Its Adaptor Molecules

Naoko Matsunaga, Noboru Tsuchimori, Tatsumi Matsumoto et al. · Molecular Pharmacology · 2010 · 567 citations

A Novel Cyclohexene Derivative, Ethyl (6R)-6-[N-(2-Chloro-4-fluorophenyl)sulfamoyl]cyclohex-1-ene-1-carboxylate (TAK-242), Selectively Inhibits Toll-Like Receptor 4-Mediated Cytokine Production through Suppression of Intracellular Signaling

Masayuki Ii, Naoko Matsunaga, Kaoru Hazeki et al. · Molecular Pharmacology · 2005 · 363 citations

Analysis of binding site for the novel small‐molecule TLR4 signal transduction inhibitor TAK‐242 and its therapeutic effect on mouse sepsis model

Katsunori Takashima, Naoko Matsunaga, Mitsuhiro Yoshimatsu et al. · British Journal of Pharmacology · 2009 · 240 citations · Full text

Clofazimine broadly inhibits coronaviruses including SARS-CoV-2

Shuofeng Yuan, Xin Yin, Xiangzhi Meng et al. · Nature · 2021 · 200 citations · Full text